{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hse:P00760:a retrieved successfully",
    "request_url": "https://api.moalmanac.org/indications?indication_id=ind%3Ahse%3AP00760%3Aa",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.00158,
    "timestamp_received": "2026-11-09T16:13:52.722989Z",
    "timestamp_returned": "2026-11-09T16:13:52.724569Z",
    "trace_id": "01a899be-88e2-49aa-bdb5-ac0171965455"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-10-08"
  },
  "data": [
    {
      "id": "ind:hse:P00760:a",
      "type": "Indication",
      "description": "For the treatment of paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have no satisfactory treatment options",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2024-01-16:0",
          "type": "Contribution",
          "description": "Adding HSE approvals for reimbursement to database",
          "date": "2024-01-16",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:hse:2023-05-01:0",
          "type": "Contribution",
          "description": "Indication approved for reimbursement.",
          "date": "2023-05-01",
          "contributor": {
            "id": "agent:org:hse",
            "type": "Agent",
            "agentType": "organization",
            "name": "Health Service Executive",
            "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:hse:P00760",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Larotrectinib Monotherapy - Paediatric. NCCP National SACT Regimen. HSE.",
          "title": null,
          "aliases": [],
          "description": "Larotrectinib Monotherapy - Paediatric, 2024, version number 3, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6810/P760_V3_Larotrectinib_Therapy_Paediatric.pdf",
          "urls": [
            "https://healthservice.hse.ie/documents/6810/P760_V3_Larotrectinib_Therapy_Paediatric.pdf"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:hse",
                "type": "Agent",
                "agentType": "organization",
                "name": "Health Service Executive",
                "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": null,
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": null,
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "publication_date",
              "value": "2023-04-28",
              "description": "The publication date for the document."
            },
            {
              "name": "regulatory_identifier",
              "value": null,
              "description": "Identifier assigned by the regulatory agency, such as an FDA application number (e.g. NDA208716, BLA125427) or an EMA product number (e.g. EMEA/H/C/006184)."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "extensions": [
        {
          "name": "status",
          "value": "Approved",
          "description": "Current approval status."
        },
        {
          "name": "statement description",
          "value": "The Republic of Ireland's Health Service Executive (HSE) has approved larotrectinib monotherapy for reimbursement for the treatment of pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. This indication is for patients whose disease is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.",
          "description": "The description text for all Statements derived from this Indication."
        },
        {
          "name": "reimbursement_scheme",
          "value": "CDS",
          "description": "Current scheme used to reimburse indication."
        },
        {
          "name": "reimbursement_comment",
          "value": "Subject to a managed access protocol",
          "description": "More details about the current reimbursement scheme(s)."
        }
      ]
    }
  ]
}